4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology  Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant de

ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expens

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC

Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology  The company's new Orion cortical stimulation system for visual perception, designed to treat most common forms of blindness, successfully completed a six-year Early Feasibility Study Cortigent is also developing a new medical device aimed at improving the recovery of arm and hand motion in patients suffering from paralysis due to stroke ALAMEDA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that its wholly-own

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of NPM-139 while securing financial position into 2027 ALAMEDA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reporte

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and a concurrent private placement of 3,703,703 shares of its common stock at an offering price of $1.62 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $15.7 million, before deducting fees and offering expen

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and concurrent private placement of 3,703,703 shares of its common stock at an offering price of $1.62 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC

ALAMEDA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that Chief Executive Officer Adam Mendelsohn, Ph.D., will provide a Company Presentation at the ThinkEquity Conference on October 30, 2025 in New York. Event details are as follows:Presentation Date: Thursday, October 30, 2025Presentation Time: 1:30 p.m. Eastern TimeLocation: Lotus Suite East, The Mandarin Oriental Hotel, 80 Columbus Circle, New York, 10023 A webcast of the Vivani ThinkEquity Conference presentation will be available on the Investors page of the

ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that the Company will temporarily withdraw the previously announced record date for the planned spin-off of Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant devices with cutting-edge neuromodulation technology, due to delays arising from the current shutdown of the U.S. federal government. Vivani expects to reestablish and announce a new record date as soon as possible. ThinkEquity is acting as the exclusive financial advisor to

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community the opportunity to engage directly with Vivani President and CEO Adam Mendelsohn, Ph.D. Dr. Mendelsohn will provide an overview of the Company and, time permitting, open the

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

424B5 - Vivani Medical, Inc. (0001266806) (Filer)

10-Q - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

424B5 - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

8-K - Vivani Medical, Inc. (0001266806) (Filer)

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent's new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke Vivani to sharpen focus on development of miniature, ultra long-acting GLP-1 implants for weight loss management and treatment of type 2 diabetes with once or twice-year

SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

SC 13D - Vivani Medical, Inc. (0001266806) (Subject)